Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.

Michael R. Migden,Danny Rischin,Medha Sasane,Vera Mastey,Anna C. Pavlick,Chrysalyne D. Schmults,Zhen Chen,Alexander Guminski,Axel Hauschild,Denise Bury,Anne Lynn S. Chang,Guilherme Rabinowits,Sherrif F. Ibrahim,Israel Lowy,Matthew G. Fury,Siyu Li,Chieh-I Chen

Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.

2020

Michael R. Migden
Danny Rischin
Medha Sasane
Vera Mastey
Anna C. Pavlick
Chrysalyne D. Schmults
Zhen Chen
Alexander Guminski
Axel Hauschild
Denise Bury
Anne Lynn S. Chang
Guilherme Rabinowits
Sherrif F. Ibrahim
Israel Lowy
Matthew G. Fury
Siyu Li
Chieh-I Chen

10033Background: Cemiplimab-rwlc (cemiplimab), a PD-1 Inhibitor, showed a robust clinical response in patients (pts) with metastatic (mCSCC) or locally advanced (laCSCC) CSCC not eligible for curat...

Keywords:

Oncology
health related quality of life
Cutaneous squamous cell carcinoma
Physical therapy
post hoc
Internal medicine
in patient
Clinical trial
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations